Applied Therapeutics, Inc.
APLT
$0.441
-$0.0191-4.15%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -98.22% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -98.22% | -- | -- |
| Cost of Revenue | 37.49% | -15.81% | -23.33% | -3.11% | -- |
| Gross Profit | -36.36% | 17.02% | -128.00% | 1.91% | -- |
| SG&A Expenses | 219.26% | 99.89% | 62.39% | -26.77% | -24.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.74% | 19.84% | -1.09% | 7.22% | -19.95% |
| Operating Income | -91.95% | -19.00% | -94.26% | -10.73% | 19.95% |
| Income Before Tax | -61.89% | 109.80% | -728.04% | -161.13% | -121.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.89% | 109.80% | -728.04% | -161.13% | -121.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.89% | 109.80% | -728.04% | -161.13% | -121.82% |
| EBIT | -91.95% | -19.00% | -94.26% | -10.73% | 19.95% |
| EBITDA | -91.95% | -19.01% | -94.26% | -10.74% | 19.95% |
| EPS Basic | -1.69% | 105.37% | -272.32% | -18.00% | -17.44% |
| Normalized Basic EPS | -1.64% | 105.43% | -272.42% | -17.64% | -17.50% |
| EPS Diluted | -1.69% | 65.21% | -272.22% | -18.00% | -17.44% |
| Normalized Diluted EPS | -1.64% | 105.13% | -272.42% | -17.64% | -17.50% |
| Average Basic Shares Outstanding | 59.20% | 82.10% | 122.36% | 121.30% | 88.90% |
| Average Diluted Shares Outstanding | 59.20% | 92.80% | 122.36% | 121.30% | 88.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
